The Potential Impact of Maintaining a 3-Hour IV Thrombolysis Window: How Many More Patients can we Safely Treat?

BACKGROUND: In 2008, the European Cooperative Acute Stroke Study-3 (ECASS-3) demonstrated that intravenous-tissue plasminogen activator could be safely administered for acute stroke patients presenting between 3 and 4.5 hours from symptom onset. Recently, the Food and Drug Administration rejected ex...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lyerly, Michael J., Albright, Karen C., Boehme, Amelia K., Shahripour, Reza Bavarsad, Houston, James T., Rawal, Pawan V., Kapoor, Niren, Alvi, Muhammad, Sisson, April, Alexandrov, Anne W., Alexandrov, Andrei V.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3901990/
https://ncbi.nlm.nih.gov/pubmed/24471140
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados